Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens

NCT01644643 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01644643
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01644643 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2013
Completion date
September 30, 2014
Enrollment
345 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

complicated intra-abdominal infection, complicated urinary tract infection